QUOTIENT THERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 18 Dec 2025)
What this means for you
Not registered yet, but its 26 May 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98015218
- Mark type
- Stylized text
- Filed
- 26 May 2023
- Published for opposition
- 30 Apr 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
Owner
- QUOTIENT THERAPEUTICS, INC., CAMBRIDGE, MA, US
- QUOTIENT THERAPEUTICS, INC., CAMBRIDGE, MA, US
- Flagship Labs 86, Inc., Cambridge, MA, US
Prosecution history
- 19 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Dec 2025 — SOU EXTENSION 3 GRANTED
- 18 Dec 2025 — SOU EXTENSION 3 FILED
- 18 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Jun 2025 — SOU EXTENSION 2 GRANTED
- 18 Jun 2025 — SOU EXTENSION 2 FILED
- 18 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Dec 2024 — SOU EXTENSION 1 GRANTED
- 23 Dec 2024 — SOU EXTENSION 1 FILED
- 23 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 25 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Apr 2024 — PUBLISHED FOR OPPOSITION